Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Sep 3, 2024 · Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the...
Pipeline - Atara Biotherapeutics
Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases.
Atara Biotherapeutics Provides Update on Clinical Programs …
3 days ago · THOUSAND OAKS, Calif., January 21, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus …
Atara Biotherapeutics (ATRA)
Nov 12, 2024 · Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly …
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell …
4 days ago · Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15 million in funding through an equity line of credit. Price Action: ATRA stock is down 4.09% …
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16, 2025 · The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a rare cancer that develops after organ or stem …
Atara Biotherapeutics Provides Regulatory and Business Update …
Jan 16, 2025 · THOUSAND OAKS, Calif., January 16, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus …
About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Atara hit with cell therapy clinical hold after FDA inspection
3 days ago · After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline of T-cell immunotherapies. Atara on Tuesday …